Entropy Technologies LP Buys 2,259 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Entropy Technologies LP lifted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 69.7% during the fourth quarter, HoldingsChannel.com reports. The firm owned 5,500 shares of the company’s stock after purchasing an additional 2,259 shares during the quarter. Entropy Technologies LP’s holdings in IDEXX Laboratories were worth $2,274,000 as of its most recent filing with the SEC.

Other institutional investors have also added to or reduced their stakes in the company. FSA Wealth Management LLC purchased a new stake in shares of IDEXX Laboratories in the third quarter worth about $25,000. E Fund Management Hong Kong Co. Ltd. increased its holdings in IDEXX Laboratories by 5,700.0% during the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock worth $29,000 after acquiring an additional 57 shares during the period. Retirement Wealth Solutions LLC purchased a new stake in IDEXX Laboratories in the 4th quarter worth approximately $31,000. Mowery & Schoenfeld Wealth Management LLC lifted its stake in IDEXX Laboratories by 750.0% in the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock worth $34,000 after purchasing an additional 60 shares in the last quarter. Finally, Ashton Thomas Securities LLC bought a new position in IDEXX Laboratories in the 3rd quarter valued at $37,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on IDXX shares. Morgan Stanley lowered their price objective on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 29th. StockNews.com downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, February 5th. Leerink Partnrs upgraded shares of IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Piper Sandler reiterated a “neutral” rating and set a $435.00 target price (down from $520.00) on shares of IDEXX Laboratories in a research report on Monday, November 4th. Finally, Bank of America boosted their price target on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 4th. Four equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $524.38.

Insider Buying and Selling at IDEXX Laboratories

In other news, Director Sophie V. Vandebroek sold 344 shares of the business’s stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total value of $144,631.36. Following the completion of the sale, the director now owns 905 shares of the company’s stock, valued at approximately $380,498.20. The trade was a 27.54 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 2.11% of the company’s stock.

IDEXX Laboratories Price Performance

IDXX stock opened at $459.78 on Monday. The firm has a market cap of $37.65 billion, a P/E ratio of 43.09, a P/E/G ratio of 3.47 and a beta of 1.37. The firm’s fifty day moving average is $428.35 and its 200 day moving average is $453.44. IDEXX Laboratories, Inc. has a 52 week low of $398.50 and a 52 week high of $583.39. The company has a debt-to-equity ratio of 0.28, a quick ratio of 1.03 and a current ratio of 1.31.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.